TY  - JOUR
T1  - EFfects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years
AU  - Prosser LA, Meltzer MI, Fiore A, et al
Y1  - 2011/02/01
N1  - 10.1001/archpediatrics.2010.182
JO  - Archives of Pediatrics & Adolescent Medicine
SP  - 112
EP  - 118
VL  - 165
IS  - 2
N2  - 
Live attenuated influenza vaccine (LAIV) is approved for children 2 years or older without a history of wheezing or asthma.1- 3 A recent randomized controlled trial among children younger than 5 years of age found that intranasal LAIV was more effective in preventing laboratory-confirmed influenza compared with inactivated influenza vaccine (IIV), yet these data also suggested an increase in adverse events, such as wheezing, in children younger than 5 years of age who receive LAIV compared with IIV.1 Given that a possible increase in adverse events was of potential concern to providers and parents, we sought to evaluate the effect of these events on cost-effectiveness results. The objective of this study was to evaluate the cost-effectiveness of LAIV using new data on adverse events.

SN  - 1072-4710
M3  - doi: 10.1001/archpediatrics.2010.182
UR  - http://dx.doi.org/10.1001/archpediatrics.2010.182
ER  -